Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™
-- FDA feedback consistent with FDA’s preliminary communication in September-- --Company requesting meeting with FDA to discuss next steps required to resubmit the NDA-- FREMONT, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA
FREMONT, Calif. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™
View HTML
Toggle Summary Zosano Pharma to Present at the Cantor Virtual Global Healthcare Conference
FREMONT, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the Cantor Virtual Global Healthcare Conference on
View HTML
Toggle Summary Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
FREMONT, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the H.C.
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8 million,
View HTML
Toggle Summary Zosano Pharma Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered
View HTML
Toggle Summary Zosano Pharma Announces Agreement to Collaborate with Mitsubishi Tanabe Pharma Corporation
FREMONT, Calif. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation , a global pharmaceutical company that develops
View HTML
Toggle Summary Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™
Agreement outlines commercialization and distribution execution strategy upon FDA approval EVERSANA to provide commercial services of approximately $250 million over 5 years FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020 , as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma to Present at the BTIG Biotechnology Conference 2020
FREMONT, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday,
View HTML